1
|
Flinn MA, Alvarez S, Knas MC, Alencar V, Paddock S, Zhou X, Buddell T, Jamal A, Liu P, Drnevich J, Patterson M, Link B, Omeara C. Abstract P2049: Myofibroblast Depletion Of Yap And Wwtr1 Improves Cardiac Function After Myocardial Infarction Via Ccn3 Suppression. Circ Res 2022. [DOI: 10.1161/res.131.suppl_1.p2049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The Hippo-Yap pathway is an area of interest in cardiac fibroblasts, as inhibition Lats1/2 promotes substantial fibrosis and Yap/Wwtr1 facilitate maturation of fibroblasts to myofibroblasts. While the Hippo-Yap pathway has been characterized in resting and activated fibroblasts, we take the novel approach of investigating its role in myofibroblasts. We assess depletion of Yap alone (
Yap
fl/fl
;Postn
MCM
) or Yap and Wwtr1 (
Yap
fl/fl
;Wwtr1
fl/+
;Postn
MCM
) in myofibroblasts immediately following myocardial infarction and focus on identifying and validating downstream factors mediating pathological remodeling in mice. Following injury, depletion of Yap alone had no effect on heart function, but depletion of Yap and Wwtr1 resulted in improved ejection fraction and fractional shortening at 60 days post injury.
Yap
fl/fl
,
Wwtr1
fl/+
;Postn
MCM
hearts also displayed smaller scars, reduced interstitial fibrosis, and more denatured collagen. Single cell RNA sequencing of interstitial cells 7 days post injury showed suppression of pro-fibrotic and pro-inflammatory genes and suppression of a matrifibrocyte phenotype in fibroblasts derived from the
Yap
fl/fl
,
Wwtr1
fl/+
;Postn
MCM
heart. Analysis of
in vivo
and
in vitro
transcriptomics revealed depletion of Yap/Wwtr1 resulted in dramatically decreased fibroblast expression of the matricellular protein Ccn3. Administration of recombinant CCN3 to mice following injury aggravated cardiac function and scarring over the course of 28 days. Thus, we show Yap/Wwtr1 depletion in myofibroblasts attenuates fibrosis and significantly improves cardiac outcomes after injury and identify Ccn3 as a novel factor that contributes to adverse cardiac function. Given therapeutic strategies would likely be implemented after myocardial infarction when myofibroblasts are already activated, our work suggests targeting Yap and Wwtr1, or Ccn3 directly as an approach for suppressing pathological remodeling.
Collapse
Affiliation(s)
| | | | | | | | | | - Xiaoxu Zhou
- Institute of Translational Medicine, Zhejiang, China
| | | | | | | | | | | | | | | |
Collapse
|
2
|
Ferree S, Beeres F, Rompen I, Link B, Babst R, van de Wall B. Conservative treatment versus reversed shoulder prothesis for proximal humerus fractures in the elderly: A meta-analysis of observational studies and randomised clinical trials. Br J Surg 2022. [DOI: 10.1093/bjs/znac187.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Objective
The treatment of complex proximal humerus fractures in elderly patients is not yet fully eluci-dated. Of all treatment options reverse shoulder arthroplasty (RSA) and non operative treat-ment (NOT) appear to provide the best results. Evidence to guide the choice between the two is sparse. Therefore, this review provides an overview of the available evidence on RSA versus non-operative treatment.
Methods
Studies comparing RSA and NOT were included for direct comparison by systematic re-view and pooled analysis for patient rated outcome and range of motion. Additionally, indirect comparison of case-series and non-comparative studies on either treatment modalities was performed separately.
Results
Comparative: Reverse shoulder arthroplasty resulted in better patient rated outcome scores and better range of motion. Pain and treatment satisfaction scores were better after RSA. Non comparative studies reported similar patient rated and range of motion scores for both RSA and after NOT.
Conclusion
The functional and range of motion outcomes after RSA seem satisfactory and potentially superior to NOT in elderly patients. The complication rate is acceptably low and an overall revision rate of 5% was found. These results should however be viewed in light of distinct differences in patient characteristics between treatment groups.
Collapse
Affiliation(s)
- S Ferree
- Department of Trauma Surgery, University Medical Center Utrecht , Utrecht, The Netherlands
| | - F Beeres
- Department of Orthopaedics and Trauma Surgery, Cantonal Hospital Lucerne , Lucerne, Switzerland
| | - I Rompen
- Department of Orthopaedics and Trauma Surgery, Cantonal Hospital Lucerne , Lucerne, Switzerland
| | - B Link
- Department of Orthopaedics and Trauma Surgery, Cantonal Hospital Lucerne , Lucerne, Switzerland
| | - R Babst
- Department of Health Sciences, University of Lucerne , Lucerne, Switzerland
| | - B van de Wall
- Department of Orthopaedics and Trauma Surgery, Cantonal Hospital Lucerne , Lucerne, Switzerland
| |
Collapse
|
3
|
Eckburg A, Mott S, Dittmer M, Zafar F, Link B, Liu V. The frequency and significance of radiographic findings in the staging workup of patients with mycosis fungoides and Sezary syndrome. Int J Dermatol 2022; 62:e315-e318. [PMID: 35506495 DOI: 10.1111/ijd.16178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/26/2021] [Revised: 01/31/2022] [Accepted: 03/11/2022] [Indexed: 11/29/2022]
Affiliation(s)
- Alexandra Eckburg
- University of Iowa Carver College of Medicine Iowa City, Iowa City, Iowa, USA
| | - Sarah Mott
- University of Iowa Hospital and Clinic Iowa City, Iowa City, Iowa, USA
| | - Martin Dittmer
- Saint Louis University Hospital St. Louis, St. Louis, Missouri, USA
| | - Faraaz Zafar
- Marshfield Clinic Marshfield, Marshfield, Wisconsin, USA
| | - Brian Link
- University of Iowa Hospital and Clinic Iowa City, Iowa City, Iowa, USA
| | - Vincent Liu
- University of Iowa Hospital and Clinic Iowa City, Iowa City, Iowa, USA
| |
Collapse
|
4
|
Thompson HJ, King BJ, Link B, Liu V. Paraneoplastic erythema annulare centrifugum associated with mycosis fungoides. JAAD Case Rep 2021; 17:65-68. [PMID: 34901359 PMCID: PMC8640728 DOI: 10.1016/j.jdcr.2021.09.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- Hannah J. Thompson
- University of Iowa Carver College of Medicine, Iowa City, Iowa
- Department of Dermatology, University of Iowa, Iowa City, Iowa
- Correspondence to: Hannah J. Thompson, BS, Department of Dermatology, University of Iowa, 200 Hawkins Drive 40024 PFP, Iowa City, Iowa 52242.
| | | | - Brian Link
- Department of Medicine, Division of Hematology-Oncology, University of Iowa, Iowa City, Iowa
| | - Vincent Liu
- University of Iowa Carver College of Medicine, Iowa City, Iowa
- Department of Dermatology, University of Iowa, Iowa City, Iowa
- Department of Pathology, University of Iowa, Iowa City, Iowa
| |
Collapse
|
5
|
van de Wall B, van Veelen N, Babst R, Link B, Knobe M, Beeres F. ORIF versus nailing for humeral shaft fractures: A meta-analysis and systematic review of randomised clinical trials and observational studies. Br J Surg 2021. [DOI: 10.1093/bjs/znab202.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
Objective
This meta-analysis aims to compare open reduction and internal fixation with a plate (ORIF) versus nailing for humeral shaft fractures in terms of healing, complications, general quality of life and shoulder/elbow function.
Methods
PubMed/Medline/Embase/CENTRAL/CINAHL was searched for both randomised clinical trials (RCT) and observational studies comparing ORIF with nailing for humeral shaft fractures. Effect estimates were pooled across studies using random effects models and presented as weighted odds ratio (OR) or risk difference (RD) with corresponding 95% confidence interval (95%CI). Subgroup analysis was performed stratified by study design (RCTs and observational studies).
Results
A total of ten RCT's (525 patients) and eighteen observational studies (4906 patients) were included. The effect estimates obtained from observational studies and RCT's were similar in direction and magnitude. More patients treated with nailing required re-intervention (RD: 2%; OR 2.0, 95%CI 1.0 – 3.8) with shoulder impingement being the most predominant indication (17%). Temporary radial nerve palsy secondary to operation occurred less frequently in the nailing group (RD: 2%; OR 0.4, 95% CI 0.3 – 0.6). Notably, all but one of the radial nerve palsies resolved sponta-neously in each groups. Nailing leads to a faster time to union (mean difference: -1.9 weeks, 95%CI -2.9 – -0.9), lower infection rate (RD: 2%; OR: 0.5, 95%CI 0.3 – 0.7) and shorter operation duration (mean difference: -26 minutes, 95%CI -37 – -14). No differences were found regarding non-union, general quality of life, functional shoulder scores, and total upper extremity scores.
Conclusion
Nailing carries a lower risk of infection, postoperative radial nerve palsy, shorter operation duration, and time to union. Absolute differences, however, are small and almost all patients with radial nerve palsy recovered spontaneously. Satisfactory results can be achieved with both treatment modalities and both techniques have their inherent pros and cons.
Collapse
Affiliation(s)
- B van de Wall
- Department of Orthopaedics and Trauma Surgery, Cantonal Hospital Lucerne, Lucerne, Switzerland
| | - N van Veelen
- Department of Orthopaedics and Trauma Surgery, Cantonal Hospital Lucerne, Lucerne, Switzerland
| | - R Babst
- Department of Orthopaedics and Trauma Surgery, Cantonal Hospital Lucerne, Lucerne, Switzerland
| | - B Link
- Department of Orthopaedics and Trauma Surgery, Cantonal Hospital Lucerne, Lucerne, Switzerland
| | - M Knobe
- Department of Orthopaedics and Trauma Surgery, Cantonal Hospital Lucerne, Lucerne, Switzerland
| | - F Beeres
- Department of Orthopaedics and Trauma Surgery, Cantonal Hospital Lucerne, Lucerne, Switzerland
| |
Collapse
|
6
|
Clausen M, Maurer M, Ulrichsen S, Larsen T, Himmelstrup B, Ronnov-Jessen D, Link B, Feldman A, Slager S, Nowakowski G, Thompson C, Pedersen P, Madsen J, Pedersen R, Gørløv J, Cerhan J, d'Amore F. PRE-TREATMENT HEMOGLOBIN AND OUTCOME IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ANTHRACYCLINE CONTAINING CHEMOTHERAPY. Hematol Oncol 2019. [DOI: 10.1002/hon.88_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M.R. Clausen
- Department of Hematology; Aarhus University Hospital; Aarhus Denmark
| | - M. Maurer
- Department of Health Sciences Research; Mayo Clinic; Rochester United States
| | - S.P. Ulrichsen
- Department of Clinical Epidemiology; Aarhus University Hospital; Aarhus Denmark
| | - T.S. Larsen
- Department of Hematology; Odense University Hospital; Odense Denmark
| | - B. Himmelstrup
- Department of Hematology; Zealand University Hospital; Roskilde Denmark
| | | | - B. Link
- Department of Medicine; University of Iowa; Iowa City United States
| | - A. Feldman
- Department of Laboratory Medicine and Pathology; Mayo Clinic; Rochester United States
| | - S. Slager
- Department of Health Sciences Research; Mayo Clinic; Rochester United States
| | - G. Nowakowski
- Department of Health Sciences Research; Mayo Clinic; Rochester United States
| | - C. Thompson
- Department of Health Sciences Research; Mayo Clinic; Rochester United States
| | - P.T. Pedersen
- Department of Hematology; Sydvestjysk Sygehus; Esbjerg Denmark
| | - J. Madsen
- Department of Hematology; Aalborg University Hospital; Aalborg Denmark
| | - R.S. Pedersen
- Department of Hematology; Hospitalsenheden Vest; Holstebro Denmark
| | - J.S. Gørløv
- Department of Hematology; Rigshospitalet; Copenhagen Copenhagen Denmark
| | - J.R. Cerhan
- Department of Health Sciences Research; Mayo Clinic; Rochester United States
| | - F. d'Amore
- Department of Hematology; Aarhus University Hospital; Aarhus Denmark
| |
Collapse
|
7
|
Borcherding N, Voigt A, Liu V, Link B, Zhang W, Jabbari A. 169 Single-cell profiling of cutaneous T-cell lymphoma reveals underlying heterogeneity predicting disease progression. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
8
|
Clouston S, Richards M, Smith D, Mukherjee S, Zhang Y, Hou W, Link B. EDUCATION AND THE ONSET OF COGNITIVE PATHOLOGY: A LONGITUDINAL ANALYSIS OF ACCELERATED COGNITIVE DECLINE. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.174] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | - M Richards
- Unit for Lifelong Health and Ageing and University College London
| | | | | | | | | | - B Link
- University of California at Riverside
| |
Collapse
|
9
|
Cox AG, Tsomides A, Yimlamai D, Hwang KL, Miesfeld J, Galli GG, Fowl BH, Fort M, Ma KY, Sullivan MR, Hosios AM, Snay E, Yuan M, Brown KK, Lien EC, Chhangawala S, Steinhauser ML, Asara JM, Houvras Y, Link B, Vander Heiden MG, Camargo FD, Goessling W. Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth. EMBO J 2018; 37:embj.2018100294. [PMID: 30348863 DOI: 10.15252/embj.2018100294] [Citation(s) in RCA: 69] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2018] [Revised: 09/12/2018] [Accepted: 09/13/2018] [Indexed: 12/14/2022] Open
Abstract
The Hippo pathway and its nuclear effector Yap regulate organ size and cancer formation. While many modulators of Hippo activity have been identified, little is known about the Yap target genes that mediate these growth effects. Here, we show that yap -/- mutant zebrafish exhibit defects in hepatic progenitor potential and liver growth due to impaired glucose transport and nucleotide biosynthesis. Transcriptomic and metabolomic analyses reveal that Yap regulates expression of glucose transporter glut1, causing decreased glucose uptake and use for nucleotide biosynthesis in yap -/- mutants, and impaired glucose tolerance in adults. Nucleotide supplementation improves Yap deficiency phenotypes, indicating functional importance of glucose-fueled nucleotide biosynthesis. Yap-regulated glut1 expression and glucose uptake are conserved in mammals, suggesting that stimulation of anabolic glucose metabolism is an evolutionarily conserved mechanism by which the Hippo pathway controls organ growth. Together, our results reveal a central role for Hippo signaling in glucose metabolic homeostasis.
Collapse
Affiliation(s)
- Andrew G Cox
- Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Allison Tsomides
- Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Dean Yimlamai
- Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Katie L Hwang
- Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.,Harvard/MIT MD-PhD Program, Harvard Medical School, Boston, MA, USA
| | | | - Giorgio G Galli
- Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Brendan H Fowl
- Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Michael Fort
- Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Kimberly Y Ma
- Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Mark R Sullivan
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Aaron M Hosios
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Erin Snay
- Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Min Yuan
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Kristin K Brown
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Evan C Lien
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.,Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Sagar Chhangawala
- Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY, USA
| | - Matthew L Steinhauser
- Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.,Harvard Stem Cell Institute, Cambridge, MA, USA.,Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - John M Asara
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Yariv Houvras
- Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY, USA
| | - Brian Link
- Medical College of Wisconsin, Milwaukee, WI, USA
| | - Matthew G Vander Heiden
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.,Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - Fernando D Camargo
- Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.,Harvard Stem Cell Institute, Cambridge, MA, USA
| | - Wolfram Goessling
- Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA .,Harvard Stem Cell Institute, Cambridge, MA, USA.,Broad Institute of MIT and Harvard, Cambridge, MA, USA.,Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.,Harvard-MIT Division of Health Sciences and Technology, Boston, MA, USA
| |
Collapse
|
10
|
Holahan HM, Farah RS, Fitz S, Mott SL, Ferguson NN, McKillip J, Link B, Liu V. Health-related quality of life in patients with cutaneous T-cell lymphoma? Int J Dermatol 2018; 57:1314-1319. [DOI: 10.1111/ijd.14132] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/24/2017] [Revised: 05/31/2018] [Accepted: 06/13/2018] [Indexed: 01/21/2023]
Affiliation(s)
- Heather M. Holahan
- Rutgers-New Jersey Medical School; Department of Dermatology; University of Iowa Hospitals and Clinics; Iowa City IA USA
| | - Ronda S. Farah
- Department of Dermatology; University of Minnesota; Minneapolis MN USA
| | - Sara Fitz
- Medical Associates Clinic & Health Plans; Dubuque IA USA
| | - Sarah L. Mott
- University of Iowa Hospitals and Clinics; Holden Comprehensive Cancer Center; Iowa City IA USA
| | - Nkanyezi N. Ferguson
- Department of Dermatology; University of Iowa Hospitals and Clinics; Iowa City IA USA
| | - Julie McKillip
- Department of Dermatology; University of Iowa Hospitals and Clinics; Iowa City IA USA
| | - Brian Link
- Department of Internal Medicine-Hematology, Oncology, and Blood and Marrow Transplantation; University of Iowa Hospitals and Clinics; Iowa City IA USA
| | - Vincent Liu
- Departments of Dermatology and Pathology; University of Iowa Hospitals and Clinics; Iowa City IA USA
| |
Collapse
|
11
|
Huet S, Tesson B, Jais J, Feldman A, Magnano L, Thomas E, Traverse-Glehen A, Albaud B, Xerri L, Ansell S, Tarte K, Boyault S, Haioun C, Link B, Feugier P, Lopez-Guillermo A, Brice P, Hayette S, Jardin F, Offner F, Gentien D, Viari A, Campo E, Cerhan J, Salles G. GENE-EXPRESSION PROFILING PREDICTS DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_103] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- S. Huet
- Laboratoire d'Hématologie; Hospices Civils de Lyon; Pierre-Bénite France
| | - B. Tesson
- Biostatistiques; Institut Carnot-Calym; Pierre-Bénite France
| | - J. Jais
- Biostatistiques; Institut Carnot-Calym; Pierre-Bénite France
| | - A.L. Feldman
- Department of Laboratory Medicine and Pathology, Mayo Clinic; Rochester USA
| | - L. Magnano
- Department of Anatomic Pathology, Hospital Clinic, IDIBAPS, Ciberonc; University of Barcelona; Barcelona Spain
| | - E. Thomas
- Plateforme de Bioinformatique 'Gilles Thomas', Synergie Lyon Cancer; Lyon France
| | - A. Traverse-Glehen
- Laboratoire d'Hématologie; Hospices Civils de Lyon; Pierre-Bénite France
| | - B. Albaud
- Translational Research Department, Genomic platform, Institut Curie; PSL Research University; Paris France
| | - L. Xerri
- Department of Bio-Pathology, Institut Paoli-Calmettes; Aix-Marseille University; Marseille; France
| | - S. Ansell
- Hematology; Mayo Clinic; Rochester USA
| | - K. Tarte
- INSERM U917; Université Rennes 1, EFS Bretagne, CHU Rennes; Rennes France
| | - S. Boyault
- Département de Recherche Translationnelle et d'Innovation, Génomique des Cancers, Centre Léon Bérard; Lyon France
| | - C. Haioun
- Unité Hémopathies Lymphoïdes; Assistance Publique-Hopitaux de Paris; Créteil France
| | - B. Link
- Department of Medicine; University of Iowa; Iowa City USA
| | - P. Feugier
- Hematology; Nancy University Hospital; Vandoeuvre-Lès-Nancy France
| | - A. Lopez-Guillermo
- Department of Anatomic Pathology, Hospital Clinic, IDIBAPS, Ciberonc; University of Barcelona; Barcelona Spain
| | - P. Brice
- Hématologie; Assistance Publique-Hopitaux de Paris; Paris France
| | - S. Hayette
- Laboratoire d'Hématologie; Hospices Civils de Lyon; Pierre-Bénite France
| | - F. Jardin
- Inserm U1245, Henri Becquerel Comprehensive Cancer Center; Rouen France
| | - F. Offner
- Hematology; Universitat Ziekenhuis Gent; Ghent Belgium
| | - D. Gentien
- Translational Research Department, Genomic platform, Institut Curie; PSL Research University; Paris France
| | - A. Viari
- Plateforme de Bioinformatique 'Gilles Thomas', Synergie Lyon Cancer; Lyon France
| | - E. Campo
- Department of Anatomic Pathology, Hospital Clinic, IDIBAPS, Ciberonc; University of Barcelona; Barcelona Spain
| | - J.R. Cerhan
- Department of Health Sciences Research; Mayo Clinic; Rochester USA
| | - G. Salles
- Service d'hématologie Marcel Bérard; CHLS, Hospices Civils de Lyon; Pierre-Bénite France
| |
Collapse
|
12
|
Dunleavy K, Roschewski M, Abramson J, Link B, Parekh S, Jagadeesh D, Bierman P, Watson P, Peace D, Hanna W, Powell B, Melani C, Lucas A, Steinberg S, Kahl B, Friedberg J, Little R, Bartlett N, Fanale M, Noy A, Wilson W. RISK-ADAPTED THERAPY IN ADULTS WITH BURKITT LYMPHOMA: UPDATED RESULTS OF a MULTICENTER PROSPECTIVE PHASE II STUDY OF DA-EPOCH-R. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_122] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- K. Dunleavy
- Center for Cancer Research; National Cancer Institute; Bethesda USA
| | - M. Roschewski
- Center for Cancer Research; National Cancer Institute; Bethesda USA
| | - J.S. Abramson
- Center for Lymphoma; Massachusetts General Hospital; Boston USA
| | - B. Link
- Hematology-Oncology; University of Iowa Hospitals; Iowa City USA
| | - S. Parekh
- Hematology-Oncology; Icahn School of Medicine at Mount Sinai; New Yorki USA
| | - D. Jagadeesh
- Hematology-Oncology; Cleveland Clinic; Cleveland USA
| | - P. Bierman
- Hematology-Oncology; University of Nebraska Medical Center; Omaha USA
| | - P.R. Watson
- Hematology-Oncology; Kinston Medical Specialists; Kinston USA
| | - D. Peace
- Hematology-Oncology; University of Illinois; Chicago USA
| | - W. Hanna
- Hematology-Oncology; University of Tennessee Medical Center; Knoxville USA
| | - B. Powell
- Hematology-Oncology; Comprehensive Cancer Center of Wake Forest University; Winston-Salem USA
| | - C. Melani
- Center for Cancer Research; National Cancer Institute; Bethesda USA
| | - A. Lucas
- Center for Cancer Research; National Cancer Institute; Bethesda USA
| | - S.M. Steinberg
- Center for Cancer Research; National Cancer Institute; Bethesda USA
| | - B. Kahl
- Hematology-Oncology; Washington University; St. Louis USA
| | - J.W. Friedberg
- Hematology-Oncology; University of Rochester; Rochester USA
| | - R.F. Little
- Cancer Therapy Evaluation Program; National Cancer Institute; Rockville USA
| | - N.L. Bartlett
- Hematology-Oncology; Washington University; St. Louis USA
| | - M.A. Fanale
- Hematology-Oncology; MD Anderson Cancer Center; Houston USA
| | - A. Noy
- Hematology-Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - W.H. Wilson
- Center for Cancer Research; National Cancer Institute; Bethesda USA
| |
Collapse
|
13
|
Sarkozy C, Link B, Ghesquieres H, Maurer M, Nicolas-Virelizier E, Thompson C, Traverse-Glehen A, Feldman A, Allmer C, Slager S, Ansell S, Habermann T, Bachy E, Cerhan J, Salles G. CAUSE OF DEATH IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A POOLED ANALYSIS OF FRENCH AND US COHORTS. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_15] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- C. Sarkozy
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - B. Link
- Internal Medicine; University of Iowa Hospitals and Clinics; Iowa City USA
| | - H. Ghesquieres
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - M. Maurer
- Health Sciences Research; Mayo Clinic; Rochester USA
| | | | | | | | - A. Feldman
- Laboratory Medicine and Pathology, Mayo Clinic; Rochester USA
| | - C. Allmer
- Health Sciences Research; Mayo Clinic; Rochester USA
| | - S. Slager
- Health Sciences Research; Mayo Clinic; Rochester USA
| | - S. Ansell
- Medicine, Mayo Clinic; Rochester USA
| | | | - E. Bachy
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - J. Cerhan
- Hematology; Mayo Clinic; Rochester USA
| | - G. Salles
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| |
Collapse
|
14
|
Manso BA, Wenzl K, Asmann YW, Maurer MJ, Manske M, Yang ZZ, Slager SL, Nowakowski GS, Ansell SM, Witzig TE, Feldman AL, Rimsza L, Link B, Cerhan JR, Novak AJ. Whole-exome analysis reveals novel somatic genomic alterations associated with cell of origin in diffuse large B-cell lymphoma. Blood Cancer J 2017; 7:e553. [PMID: 28430174 PMCID: PMC5436076 DOI: 10.1038/bcj.2017.33] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Affiliation(s)
- B A Manso
- Department of Immunology, Mayo Clinic, Rochester, MN, USA
| | - K Wenzl
- Division of Hematology, Mayo Clinic, Rochester, MN, USA
| | - Y W Asmann
- Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA
| | - M J Maurer
- Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA
| | - M Manske
- Division of Hematology, Mayo Clinic, Rochester, MN, USA
| | - Z-Z Yang
- Division of Hematology, Mayo Clinic, Rochester, MN, USA
| | - S L Slager
- Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA
| | | | - S M Ansell
- Division of Hematology, Mayo Clinic, Rochester, MN, USA
| | - T E Witzig
- Division of Hematology, Mayo Clinic, Rochester, MN, USA
| | - A L Feldman
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | - L Rimsza
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ, USA
| | - B Link
- Department of Hematology, Oncology and Blood and Marrow Transplantation, University of Iowa, Iowa City, IA, USA
| | - J R Cerhan
- Division of Epidemiology, Mayo Clinic, Rochester, MN, USA
| | - A J Novak
- Department of Immunology, Mayo Clinic, Rochester, MN, USA.,Division of Hematology, Mayo Clinic, Rochester, MN, USA
| |
Collapse
|
15
|
Demosthenous C, Han JJ, Stenson MJ, Maurer MJ, Wellik LE, Link B, Hege K, Dogan A, Sotomayor E, Witzig T, Gupta M. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. Oncotarget 2016; 6:9488-501. [PMID: 25839159 PMCID: PMC4496233 DOI: 10.18632/oncotarget.3378] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2015] [Accepted: 02/12/2015] [Indexed: 01/10/2023] Open
Abstract
Deregulated mRNA translation has been implicated in disease development and in part is controlled by a eukaryotic initiation complex eIF4F (composed of eIF4E, eIF4G and eIF4A). We demonstrate here that the cap bound fraction from lymphoma cells was enriched with eIF4G and eIF4E indicating that lymphoma cells exist in an activated translational state. Moreover, 77% (110/142) of diffuse large B cell lymphoma tumors expressed eIF4E and this was associated with an inferior event free survival. Over-expression of wild-type eIF4E (eIF4E(WT)) but not cap-mutant eIF4E (eIF4E(cap mutant)) increased the activation of the eIF4F complex. Treatment with the active-site dual mTOR inhibitor CC214-1 reduced the level of the eIF4F complex by decreasing the cap bound fraction of eIF4G and increasing the levels of 4E-BP1. CC214-1 inhibited both the cap dependent and global protein translation. CC214-1 inhibited c-Myc, and cyclin D3 translation by decreasing polysomal fractions from lymphoma cells. Inhibition of eIF4E with shRNA further decreased the CC214-1 induced inhibition of the eIF4F complex, c-Myc, cyclin D3 translation, and colony formation. These studies demonstrate that the eIF4F complex is deregulated in aggressive lymphoma and that dual mTOR therapy has therapeutic potential in these patients.
Collapse
Affiliation(s)
- Christos Demosthenous
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - Jing Jing Han
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - Mary J Stenson
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - Matthew J Maurer
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - Linda E Wellik
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - Brian Link
- Department of Internal Medicine, University of Iowa College of Medicine, IA, USA
| | | | - Ahmet Dogan
- Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - Eduardo Sotomayor
- Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
| | - Thomas Witzig
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - Mamta Gupta
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| |
Collapse
|
16
|
Reiss J, Link B, Ruan J, Furman R, Coleman M, Leonard J, Martin P. Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma. Leuk Lymphoma 2015; 56:2870-5. [DOI: 10.3109/10428194.2015.1016929] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
17
|
Cho YJ, Tang Y, Schubert S, Willardson M, Bandopadhayay P, Bergthold G, Nguyen B, Masoud S, Vue N, Balansay B, Gholamin S, Cheshier SH, Atwood SX, Whitson RJ, Lee A, Tang JY, Qi J, Beroukhim R, Wechsler-Reya R, Oro AE, Link B, Bradner JE, Cho YJ. EPIGENETIC TARGETING OF HEDGEHOG PATHWAY TRANSCRIPTIONAL OUTPUT. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou208.9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
18
|
Vaidyanathan G, Gururangan S, Bigner D, Zalutsky M, Morfouace M, Shelat A, Megan J, Freeman BB, Robinson S, Throm S, Olson JM, Li XN, Guy KR, Robinson G, Stewart C, Gajjar A, Roussel M, Sirachainan N, Pakakasama S, Anurathapan U, Hansasuta A, Dhanachai M, Khongkhatithum C, Hongeng S, Feroze A, Lee KS, Gholamin S, Wu Z, Lu B, Mitra S, Cheshier S, Northcott P, Lee C, Zichner T, Lichter P, Korbel J, Wechsler-Reya R, Pfister S, Project IPT, Li KKW, Xia T, Ma FMT, Zhang R, Zhou L, Lau KM, Ng HK, Lafay-Cousin L, Chi S, Madden J, Smith A, Wells E, Owens E, Strother D, Foreman N, Packer R, Bouffet E, Wataya T, Peacock J, Taylor MD, Ivanov D, Garnett M, Parker T, Alexander C, Meijer L, Grundy R, Gellert P, Ashford M, Walker D, Brent J, Cader FZ, Ford D, Kay A, Walsh R, Solanki G, Peet A, English M, Shalaby T, Fiaschetti G, Baulande S, Gerber N, Baumgartner M, Grotzer M, Hayase T, Kawahara Y, Yagi M, Minami T, Kanai N, Yamaguchi T, Gomi A, Morimoto A, Hill R, Kuijper S, Lindsey J, Schwalbe E, Barker K, Boult J, Williamson D, Ahmad Z, Hallsworth A, Ryan S, Poon E, Robinson S, Ruddle R, Raynaud F, Howell L, Kwok C, Joshi A, Nicholson SL, Crosier S, Wharton S, Robson K, Michalski A, Hargrave D, Jacques T, Pizer B, Bailey S, Swartling F, Petrie K, Weiss W, Chesler L, Clifford S, Kitanovski L, Prelog T, Kotnik BF, Debeljak M, Fiaschetti G, Shalaby T, Baumgartner M, Grotzer MA, Gevorgian A, Morozova E, Kazantsev I, Iukhta T, Safonova S, Kumirova E, Punanov Y, Afanasyev B, Zheludkova O, Grajkowska W, Pronicki M, Cukrowska B, Dembowska-Baginska B, Lastowska M, Murase A, Nobusawa S, Gemma Y, Yamazaki F, Masuzawa A, Uno T, Osumi T, Shioda Y, Kiyotani C, Mori T, Matsumoto K, Ogiwara H, Morota N, Hirato J, Nakazawa A, Terashima K, Fay-McClymont T, Walsh K, Mabbott D, Smith A, Wells E, Madden J, Chi S, Owens E, Strother D, Packer R, Foreman N, Bouffet E, Lafay-Cousin L, Sturm D, Northcott PA, Jones DTW, Korshunov A, Lichter P, Pfister SM, Kool M, Hooper C, Hawes S, Kees U, Gottardo N, Dallas P, Siegfried A, Bertozzi AI, Sevely A, Loukh N, Munzer C, Miquel C, Bourdeaut F, Pietsch T, Dufour C, Delisle MB, Kawauchi D, Rehg J, Finkelstein D, Zindy F, Phoenix T, Gilbertson R, Pfister S, Roussel M, Trubicka J, Borucka-Mankiewicz M, Ciara E, Chrzanowska K, Perek-Polnik M, Abramczuk-Piekutowska D, Grajkowska W, Jurkiewicz D, Luczak S, Kowalski P, Krajewska-Walasek M, Lastowska M, Sheila C, Lee S, Foster C, Manoranjan B, Pambit M, Berns R, Fotovati A, Venugopal C, O'Halloran K, Narendran A, Hawkins C, Ramaswamy V, Bouffet E, Taylor M, Singhal A, Hukin J, Rassekh R, Yip S, Northcott P, Singh S, Duhman C, Dunn S, Chen T, Rush S, Fuji H, Ishida Y, Onoe T, Kanda T, Kase Y, Yamashita H, Murayama S, Nakasu Y, Kurimoto T, Kondo A, Sakaguchi S, Fujimura J, Saito M, Arakawa T, Arai H, Shimizu T, Lastowska M, Jurkiewicz E, Daszkiewicz P, Drogosiewicz M, Trubicka J, Grajkowska W, Pronicki M, Kool M, Sturm D, Jones DTW, Hovestadt V, Buchhalter I, Jager NN, Stuetz A, Johann P, Schmidt C, Ryzhova M, Landgraf P, Hasselblatt M, Schuller U, Yaspo ML, von Deimling A, Korbel J, Eils R, Lichter P, Korshunov A, Pfister S, Modi A, Patel M, Berk M, Wang LX, Plautz G, Camara-Costa H, Resch A, Lalande C, Kieffer V, Poggi G, Kennedy C, Bull K, Calaminus G, Grill J, Doz F, Rutkowski S, Massimino M, Kortmann RD, Lannering B, Dellatolas G, Chevignard M, Lindsey J, Kawauchi D, Schwalbe E, Solecki D, McKinnon P, Olson J, Hayden J, Grundy R, Ellison D, Williamson D, Bailey S, Roussel M, Clifford S, Buss M, Remke M, Lee J, Caspary T, Taylor M, Castellino R, Lannering B, Sabel M, Gustafsson G, Fleischhack G, Benesch M, Doz F, Kortmann RD, Massimino M, Navajas A, Reddingius R, Rutkowski S, Miquel C, Delisle MB, Dufour C, Lafon D, Sevenet N, Pierron G, Delattre O, Bourdeaut F, Ecker J, Oehme I, Mazitschek R, Korshunov A, Kool M, Lodrini M, Deubzer HE, von Deimling A, Kulozik AE, Pfister SM, Witt O, Milde T, Phoenix T, Patmore D, Boulos N, Wright K, Boop S, Gilbertson R, Janicki T, Burzynski S, Burzynski G, Marszalek A, Triscott J, Green M, Foster C, Fotovati A, Berns R, O'Halloran K, Singhal A, Hukin J, Rassekh SR, Yip S, Toyota B, Dunham C, Dunn SE, Liu KW, Pei Y, Wechsler-Reya R, Genovesi L, Ji P, Davis M, Ng CG, Remke M, Taylor M, Cho YJ, Jenkins N, Copeland N, Wainwright B, Tang Y, Schubert S, Nguyen B, Masoud S, Gholamin S, Lee A, Willardson M, Bandopadhayay P, Bergthold G, Atwood S, Whitson R, Cheshier S, Qi J, Beroukhim R, Tang J, Wechsler-Reya R, Oro A, Link B, Bradner J, Cho YJ, Vallero SG, Bertin D, Basso ME, Milanaccio C, Peretta P, Cama A, Mussano A, Barra S, Morana G, Morra I, Nozza P, Fagioli F, Garre ML, Darabi A, Sanden E, Visse E, Stahl N, Siesjo P, Cho YJ, Vaka D, Schubert S, Vasquez F, Weir B, Cowley G, Keller C, Hahn W, Gibbs IC, Partap S, Yeom K, Martinez M, Vogel H, Donaldson SS, Fisher P, Perreault S, Cho YJ, Guerrini-Rousseau L, Dufour C, Pujet S, Kieffer-Renaux V, Raquin MA, Varlet P, Longaud A, Sainte-Rose C, Valteau-Couanet D, Grill J, Staal J, Lau LS, Zhang H, Ingram WJ, Cho YJ, Hathout Y, Brown K, Rood BR, Sanden E, Visse E, Stahl N, Siesjo P, Darabi A, Handler M, Hankinson T, Madden J, Kleinschmidt-Demasters BK, Foreman N, Hutter S, Northcott PA, Kool M, Pfister S, Kawauchi D, Jones DT, Kagawa N, Hirayama R, Kijima N, Chiba Y, Kinoshita M, Takano K, Eino D, Fukuya S, Yamamoto F, Nakanishi K, Hashimoto N, Hashii Y, Hara J, Taylor MD, Yoshimine T, Wang J, Guo C, Yang Q, Chen Z, Perek-Polnik M, Lastowska M, Drogosiewicz M, Dembowska-Baginska B, Grajkowska W, Filipek I, Swieszkowska E, Tarasinska M, Perek D, Kebudi R, Koc B, Gorgun O, Agaoglu FY, Wolff J, Darendeliler E, Schmidt C, Kerl K, Gronych J, Kawauchi D, Lichter P, Schuller U, Pfister S, Kool M, McGlade J, Endersby R, Hii H, Johns T, Gottardo N, Sastry J, Murphy D, Ronghe M, Cunningham C, Cowie F, Jones R, Sastry J, Calisto A, Sangra M, Mathieson C, Brown J, Phuakpet K, Larouche V, Hawkins C, Bartels U, Bouffet E, Ishida T, Hasegawa D, Miyata K, Ochi S, Saito A, Kozaki A, Yanai T, Kawasaki K, Yamamoto K, Kawamura A, Nagashima T, Akasaka Y, Soejima T, Yoshida M, Kosaka Y, Rutkowski S, von Bueren A, Goschzik T, Kortmann R, von Hoff K, Friedrich C, Muehlen AZ, Gerber N, Warmuth-Metz M, Soerensen N, Deinlein F, Benesch M, Zwiener I, Faldum A, Kuehl J, Pietsch T, KRAMER K, -Taskar NP, Zanzonico P, Humm JL, Wolden SL, Cheung NKV, Venkataraman S, Alimova I, Harris P, Birks D, Balakrishnan I, Griesinger A, Remke M, Taylor MD, Handler M, Foreman NK, Vibhakar R, Margol A, Robison N, Gnanachandran J, Hung L, Kennedy R, Vali M, Dhall G, Finlay J, Erdrich-Epstein A, Krieger M, Drissi R, Fouladi M, Gilles F, Judkins A, Sposto R, Asgharzadeh S, Peyrl A, Chocholous M, Holm S, Grillner P, Blomgren K, Azizi A, Czech T, Gustafsson B, Dieckmann K, Leiss U, Slavc I, Babelyan S, Dolgopolov I, Pimenov R, Mentkevich G, Gorelishev S, Laskov M, Friedrich C, Warmuth-Metz M, von Bueren AO, Nowak J, von Hoff K, Pietsch T, Kortmann RD, Rutkowski S, Mynarek M, von Hoff K, Muller K, Friedrich C, von Bueren AO, Gerber NU, Benesch M, Pietsch T, Warmuth-Metz M, Ottensmeier H, Kwiecien R, Faldum A, Kuehl J, Kortmann RD, Rutkowski S, Mynarek M, von Hoff K, Muller K, Friedrich C, von Bueren AO, Gerber NU, Benesch M, Pietsch T, Warmuth-Metz M, Ottensmeier H, Kwiecien R, Faldum A, Kuehl J, Kortmann RD, Rutkowski S, Yankelevich M, Laskov M, Boyarshinov V, Glekov I, Pimenov R, Ozerov S, Gorelyshev S, Popa A, Dolgopolov I, Subbotina N, Mentkevich G, Martin AM, Nirschl C, Polanczyk M, Bell R, Martinez D, Sullivan LM, Santi M, Burger PC, Taube JM, Drake CG, Pardoll DM, Lim M, Li L, Wang WG, Pu JX, Sun HD, Remke M, Taylor MD, Ruggieri R, Symons MH, Vanan MI, Bandopadhayay P, Bergthold G, Nguyen B, Schubert S, Gholamin S, Tang Y, Bolin S, Schumacher S, Zeid R, Masoud S, Yu F, Vue N, Gibson W, Paolella B, Mitra S, Cheshier S, Qi J, Liu KW, Wechsler-Reya R, Weiss W, Swartling FJ, Kieran MW, Bradner JE, Beroukhim R, Cho YJ, Maher O, Khatua S, Tarek N, Zaky W, Gupta T, Mohanty S, Kannan S, Jalali R, Kapitza E, Denkhaus D, Muhlen AZ, Rutkowski S, Pietsch T, von Hoff K, Pizer B, Dufour C, van Vuurden DG, Garami M, Massimino M, Fangusaro J, Davidson TB, da Costa MJG, Sterba J, Benesch M, Gerber NU, Mynarek M, Kwiecien R, Clifford SC, Kool M, Pietsch T, Finlay JL, Rutkowski S, Pietsch T, Schmidt R, Remke M, Korshunov A, Hovestadt V, Jones DT, Felsberg J, Goschzik T, Kool M, Northcott PA, von Hoff K, von Bueren A, Skladny H, Taylor M, Cremer F, Lichter P, Faldum A, Reifenberger G, Rutkowski S, Pfister S, Kunder R, Jalali R, Sridhar E, Moiyadi AA, Goel A, Goel N, Shirsat N, Othman R, Storer L, Korshunov A, Pfister SM, Kerr I, Coyle B, Law N, Smith ML, Greenberg M, Bouffet E, Taylor MD, Laughlin S, Malkin D, Liu F, Moxon-Emre I, Scantlebury N, Mabbott D, Nasir A, Othman R, Storer L, Onion D, Lourdusamy A, Grabowska A, Coyle B, Cai Y, Othman R, Bradshaw T, Coyle B, de Medeiros RSS, Beaugrand A, Soares S, Epelman S, Jones DTW, Hovestadt V, Wang W, Northcott PA, Kool M, Sultan M, Landgraf P, Reifenberger G, Eils R, Yaspo ML, Wechsler-Reya RJ, Korshunov A, Zapatka M, Radlwimmer B, Pfister SM, Lichter P, Alderete D, Baroni L, Lubinieki F, Auad F, Gonzalez ML, Puya W, Pacheco P, Aurtenetxe O, Gaffar A, Gros L, Cruz O, Calvo C, Navajas A, Shinojima N, Nakamura H, Kuratsu JI, Hanaford A, Eberhart C, Archer T, Tamayo P, Pomeroy S, Raabe E, De Braganca K, Gilheeney S, Khakoo Y, Kramer K, Wolden S, Dunkel I, Lulla RR, Laskowski J, Fangusaro J, Goldman S, Gopalakrishnan V, Ramaswamy V, Remke M, Shih D, Wang X, Northcott P, Faria C, Raybaud C, Tabori U, Hawkins C, Rutka J, Taylor M, Bouffet E, Jacobs S, De Vathaire F, Diallo I, Llanas D, Verez C, Diop F, Kahlouche A, Grill J, Puget S, Valteau-Couanet D, Dufour C, Ramaswamy V, Thompson E, Taylor M, Pomeroy S, Archer T, Northcott P, Tamayo P, Prince E, Amani V, Griesinger A, Foreman N, Vibhakar R, Sin-Chan P, Lu M, Kleinman C, Spence T, Picard D, Ho KC, Chan J, Hawkins C, Majewski J, Jabado N, Dirks P, Huang A, Madden JR, Foreman NK, Donson AM, Mirsky DM, Wang X, Dubuc A, Korshunov A, Ramaswamy V, Remke M, Mack S, Gendoo D, Peacock J, Luu B, Cho YJ, Eberhart C, MacDonald T, Li XN, Van Meter T, Northcott P, Croul S, Bouffet E, Pfister S, Taylor M, Laureano A, Brugmann W, Denman C, Singh H, Huls H, Moyes J, Khatua S, Sandberg D, Silla L, Cooper L, Lee D, Gopalakrishnan V. MEDULLOBLASTOMA. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Witzig TE, Maurer MJ, Stenson MJ, Allmer C, Macon W, Link B, Katzmann JA, Gupta M. Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma. Am J Hematol 2014; 89:417-22. [PMID: 24382707 DOI: 10.1002/ajh.23658] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2013] [Revised: 12/24/2013] [Accepted: 12/28/2013] [Indexed: 12/16/2022]
Abstract
The detection of serum free light (FLC) is useful in the diagnosis of several hematological diseases. The role and biological relevance of monoclonal or polyclonal FLC elevations in predicting long-term outcome in diffuse large B-cell lymphoma (DLBCL) is unknown. We determined the relationship of the type of FLC elevations to outcome, tumor genotype, and pattern of serum cytokine elevations in 276 patients with untreated DLBCL. Elevated FLC was an adverse prognostic factor through 6 years of follow-up (monoclonal, Event free survival (EFS) HR = 3.56, 95% CI: 1.88-6.76, P <0.0001; polyclonal, EFS HR = 2.56, 95% CI: 1.50-4.38, P = 0.0006). About 73% of DLBCL tumors with monoclonal FLC elevations were activated B-cell type (ABC) versus 33% from patients with normal FLC. Only ABC-DLBCL lines secreted kappa FLC in vitro and this secretion could be inhibited by the NF-κB inhibitor bortezomib. Patients with monoclonal FLC had significantly (all P <0.001) increased serum levels of IL-12, sIL-2Rα, IL-1R, and IP-10. Patients with polyclonal elevations of FLC had higher levels of IL-6 (P = 0.033), IL-8 (P =0.025), sIL2Rα (P = 0.011), and IL-1R1 (P = 0.041). The combination of elevated FLC and a CXC superfamily chemokine IP-10 predicted a particularly inferior outcome characterized by late relapse. These increased abnormal FLC and cytokines are potentially useful biomarkers for prognosis and selecting agents for untreated DLBCL.
Collapse
Affiliation(s)
- Thomas E. Witzig
- Division of Hematology; Department of Internal-Medicine; Mayo Clinic; Rochester Minnesota
| | - Matthew J. Maurer
- Department of Health Sciences Research; Mayo Clinic; Rochester Minnesota
| | - Mary J. Stenson
- Division of Hematology; Department of Internal-Medicine; Mayo Clinic; Rochester Minnesota
| | - Cristine Allmer
- Department of Health Sciences Research; Mayo Clinic; Rochester Minnesota
| | - William Macon
- Department of Laboratory Medicine and Pathology; Mayo Clinic; Rochester Minnesota
| | - Brian Link
- Department of Internal Medicine; University of Iowa College of Medicine; Iowa City Iowa
| | - Jerry A. Katzmann
- Department of Laboratory Medicine and Pathology; Mayo Clinic; Rochester Minnesota
| | - Mamta Gupta
- Division of Hematology; Department of Internal-Medicine; Mayo Clinic; Rochester Minnesota
| |
Collapse
|
20
|
Yeo NC, O'Meara C, Flister M, Cliff M, Lazar J, Link B, Jacob HJ. Shroom3, a novel GWAS renal candidate, is essential for glomerular barrier function. FASEB J 2013. [DOI: 10.1096/fasebj.27.1_supplement.955.6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Nan Cher Yeo
- Department of PhysiologyMedical College of WisconsinMilwaukeeWI
- Human and Molecular Genetics CenterMedical College of WisconsinMilwaukeeWI
| | - Caitlin O'Meara
- Department of PhysiologyMedical College of WisconsinMilwaukeeWI
- Human and Molecular Genetics CenterMedical College of WisconsinMilwaukeeWI
| | - Michael Flister
- Human and Molecular Genetics CenterMedical College of WisconsinMilwaukeeWI
| | - Michael Cliff
- Department of Cell BiologyMedical College of WisconsinMilwaukeeWI
| | - Jozef Lazar
- Human and Molecular Genetics CenterMedical College of WisconsinMilwaukeeWI
- Department of DermatologyMedical College of WisconsinMilwaukeeWI
| | - Brian Link
- Department of Cell BiologyMedical College of WisconsinMilwaukeeWI
| | - Howard J. Jacob
- Department of PhysiologyMedical College of WisconsinMilwaukeeWI
- Human and Molecular Genetics CenterMedical College of WisconsinMilwaukeeWI
| |
Collapse
|
21
|
Slager SL, Camp NJ, Conde L, Shanafelt TD, Achenbach SJ, Rabe KG, Kay NE, Novak AJ, Call TG, Bracci PM, Sille FMC, Sanchez S, Akers NK, Cunningham JM, Serie DJ, McDonnell SK, Leis JF, Wang AH, Weinberg JB, Glenn M, Link B, Vachon CM, Lanasa MC, Skibola CF, Cerhan JR. Common variants within 6p21.31 locus are associated with chronic lymphocytic leukaemia and, potentially, other non-Hodgkin lymphoma subtypes. Br J Haematol 2012; 159:572-6. [PMID: 23025533 DOI: 10.1111/bjh.12070] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2012] [Accepted: 08/27/2012] [Indexed: 11/27/2022]
Abstract
A recent meta-analysis of three genome-wide association studies of chronic lymphocytic leukaemia (CLL) identified two common variants at the 6p21.31 locus that are associated with CLL risk. To verify and further explore the association of these variants with other non-Hodgkin lymphoma (NHL) subtypes, we genotyped 1196 CLL cases, 1699 NHL cases, and 2410 controls. We found significant associations between the 6p21.31 variants and CLL risk (rs210134: P = 0·01; rs210142: P = 6·8 × 10(-3)). These variants also showed a trend towards association with some of the other NHL subtypes. Our results validate the prior work and support specific genetic pathways for risk among NHL subtypes.
Collapse
|
22
|
Link B, Wong B, Mayer J, Sullivan M, Fleetham J, Greene C. Laser-assisted hatching (LAH) of cryopreserved embryos – the significance of hole size. Fertil Steril 2012. [DOI: 10.1016/j.fertnstert.2012.07.287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
23
|
Collery RF, Link B. The retinal pigment epithelium as a model tissue to study the effects of Lrp2/megalin on BMP signaling. Dev Biol 2011. [DOI: 10.1016/j.ydbio.2011.05.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
24
|
Rehart S, Link B, Michels H, Lehr A. Differenzialdiagnostische Bedeutung von Gelenkkontrakturen – unter besonderer Berücksichtigung rheumatischer Erkrankungen und der Mucopolysaccharidose Typ I. AKTUEL RHEUMATOL 2011. [DOI: 10.1055/s-0031-1277163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
25
|
Keyes KM, Hatzenbuehler ML, McLaughlin KA, Link B, Olfson M, Grant BF, Hasin D. Stigma and treatment for alcohol disorders in the United States. Am J Epidemiol 2010; 172:1364-72. [PMID: 21044992 DOI: 10.1093/aje/kwq304] [Citation(s) in RCA: 266] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Abstract
Among a nationally representative sample of adults with an alcohol use disorder, the authors tested whether perceived stigmatization of alcoholism was associated with a lower likelihood of receiving alcohol-related services. Data were drawn from a face-to-face epidemiologic survey of 34,653 adults interviewed in 2004-2005 who were aged 20 years or older and residing in households and group quarters in the United States. Alcohol abuse/dependence was diagnosed by using the Alcohol Use Disorder and Associated Disabilities Interview Schedule-Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, version (AUDADIS-IV). The stigma measure used was the Perceived Devaluation-Discrimination Scale. The main outcome was lifetime intervention including professional services and 12-step groups for alcohol disorders. Individuals with a lifetime diagnosis of an alcohol use disorder were less likely to utilize alcohol services if they perceived higher stigma toward individuals with alcohol disorders (odds ratio = 0.37, 95% confidence interval: 0.18, 0.76). Higher perceived stigma was associated with male gender (β = -0.75; P < 0.01), nonwhite compared with non-Hispanic white race/ethnicity, lower income (β = 1.0; P < 0.01), education (β = 1.48; P < 0.01), and being previously married (β = 0.47; P = 0.02). Individuals reporting close contact with an alcohol-disordered individual (e.g., relative with an alcohol problem) reported lower perceived stigma (β = -1.70; P < 0.01). A link between highly stigmatized views of alcoholism and lack of services suggests that stigma reduction should be integrated into public health efforts to promote alcohol treatment.
Collapse
Affiliation(s)
- K M Keyes
- Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA.
| | | | | | | | | | | | | |
Collapse
|
26
|
Link B, Cui S, Baye L. Interkinetic nuclear migration, cell polarity, and retinal neurogenesis. J Vis 2010. [DOI: 10.1167/7.15.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
27
|
Muenzer J, Beck M, Eng CM, Escolar ML, Giugliani R, Guffon NH, Harmatz P, Kamin W, Kampmann C, Koseoglu ST, Link B, Martin RA, Molter DW, Muñoz Rojas MV, Ogilvie JW, Parini R, Ramaswami U, Scarpa M, Schwartz IV, Wood RE, Wraith E. Multidisciplinary management of Hunter syndrome. Pediatrics 2009; 124:e1228-39. [PMID: 19901005 DOI: 10.1542/peds.2008-0999] [Citation(s) in RCA: 122] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Hunter syndrome is a rare, X-linked disorder caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase. In the absence of sufficient enzyme activity, glycosaminoglycans accumulate in the lysosomes of many tissues and organs and contribute to the multisystem, progressive pathologies seen in Hunter syndrome. The nervous, cardiovascular, respiratory, and musculoskeletal systems can be involved in individuals with Hunter syndrome. Although the management of some clinical problems associated with the disease may seem routine, the management is typically complex and requires the physician to be aware of the special issues surrounding the patient with Hunter syndrome, and a multidisciplinary approach should be taken. Subspecialties such as otorhinolaryngology, neurosurgery, orthopedics, cardiology, anesthesiology, pulmonology, and neurodevelopment will all have a role in management, as will specialty areas such as physiotherapy, audiology, and others. The important management topics are discussed in this review, and the use of enzyme-replacement therapy with recombinant human iduronate-2-sulfatase as a specific treatment for Hunter syndrome is presented.
Collapse
Affiliation(s)
- Joseph Muenzer
- Department of Pediatrics, University of North Carolina, Chapel Hill, North Carolina 27599-7487, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Lubaroff DM, Konety BR, Link B, Gerstbrein J, Madsen T, Shannon M, Howard J, Paisley J, Boeglin D, Ratliff TL, Williams RD. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res 2009; 15:7375-80. [PMID: 19920098 DOI: 10.1158/1078-0432.ccr-09-1910] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
PURPOSE We performed a phase I clinical trial of adenovirus/prostate-specific antigen (PSA) vaccine in men with measurable metastatic hormone-refractory disease. EXPERIMENTAL DESIGN Men with measurable metastatic disease received one vaccine injection. Toxicity, immune responses, changes in PSA doubling times, and patient survival were assessed. Thirty-two patients with hormone-refractory metastatic prostate cancer were treated with a single s.c. vaccine injection at one of three dose levels, either as an aqueous solution or suspended in a Gelfoam matrix. All patients returned for physical and clinical chemistry examinations at regular intervals up to 12 months after injections. RESULTS The vaccine was deemed safe at all doses in both administration forms. There were no serious vaccine-related adverse events; the most prevalent were localized erythema/ecchymoses and cold/flu-like symptoms. Anti-PSA antibodies were produced by 34% of patients and anti-PSA T-cell responses were produced by 68%. PSA doubling time was increased in 48%, whereas 55% survived longer than predicted by the Halabi nomogram. CONCLUSIONS The adenovirus/PSA vaccine was proven safe with no serious vaccine-related adverse events. The majority of vaccinated patients produced anti-PSA T-cell responses and over half survived longer than predicted by nomogram. Although the latter data are only derived from a small number of patients in this phase I trial, they are encouraging enough to pursue further studies.
Collapse
Affiliation(s)
- David M Lubaroff
- Department of Urology, University of Iowa, Iowa City, Iowa 52242, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Norden C, Young S, Link B, Harris W. 08-P001 Interkinetic nuclear migration in the zebrafish retina: Actomyosin contraction is the prime mover. Mech Dev 2009. [DOI: 10.1016/j.mod.2009.06.308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
30
|
Boehme MWJ, Gabrio T, Dierkesmann R, Felder-Kennel A, Flicker-Klein A, Joggerst B, Kersting G, König M, Link B, Maisner V, Wetzig J, Weidner U, Behrendt H. [Sensitization to airborne ragweed pollen--a cause of allergic respiratory diseases in Germany?]. Dtsch Med Wochenschr 2009; 134:1457-63. [PMID: 19572244 DOI: 10.1055/s-0029-1225300] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
BACKGROUND AND OBJECTIVE Allergic skin and respiratory diseases show a high prevalence in most industrial countries. In addition, during the last years ragweed colonization has increased in Europe. Ambrosia pollen ( AMBROSIA ARTEMISIIFOLIA L. - common ragweed) are highly allergenic. Due to the late flowering time (august/September) of ragweed this can result in increasing health threats for allergic populations. This is of particular importance for those who already are sensitive to some grass or tree pollen. These individuals can then suffer from allergies during nearly the whole year. The present study examined the prevalence of sensitization to ragweed in German children and possible health implications. METHODS Between 2004 and 2007 sera of 1323 10-years old children in Baden Württemberg were tested in-vitro for specific IgE-antibodies against common aeroallergens including ragweed pollen. RESULTS Specific IgE-antibodies to extracts of common ragweed pollen were present in 10 - 17 % of the tested sera depending on the year of investigation. CONCLUSION The determined specific IgE-antibodies may be the result of a direct sensitization to ragweed pollen or correspond to cross-reactivity to other plants of the asteraceae subfamily or some nutritional allergens. The detection of sensitization to ragweed pollen does not prove actual allergic disease. However, a ragweed derived allergy should be considered in the differential diagnosis when allergic symptoms are present in direct connection to the flowering-time of ragweed. Ragweed plants should be removed and the spread of the plant 'restricted', as experiences in other countries with already wide spreading show.
Collapse
Affiliation(s)
- M W J Boehme
- Landesgesundheitsamt Baden-Württemberg im Regierungspräsidium Stuttgart, Stuttgart, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Kremers J, Link B. Electroretinographic responses that may reflect activity of parvo- and magnocellular post-receptoral visual pathways. J Vis 2008; 8:11.1-14. [PMID: 19146295 DOI: 10.1167/8.15.11] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2008] [Accepted: 07/29/2008] [Indexed: 11/24/2022] Open
|
32
|
Geraminejad P, Vasef M, Piette W, Link B, Stone M. Cns Involvement From Mycosis Fungoides With CD 30 Transformation. J Cutan Pathol 2008. [DOI: 10.1111/j.0303-6987.2005.320cb.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
33
|
Schneeberger A, Muenzenmaier K, Castille D, Link B. Co-occurrance of childhood trauma and adult psychosis: A picture of co-morbidity. Eur Psychiatry 2008. [DOI: 10.1016/j.eurpsy.2008.01.884] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
34
|
Link B, Miebach E, Vetter T, Schmitt D, Beck M, Meurer A. [Mucopolysaccharidoses]. Orthopade 2008; 37:24-30. [PMID: 18210085 DOI: 10.1007/s00132-007-1178-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Mucopolysaccharidoses are a family of metabolic disorders characterized by a deficiency in the catabolic lysosomal pathways. They are rare, inherited diseases which lead to progressive cellular, tissue and organ damage across a broad spectrum of phenotypes. To prevent irreversible damage early diagnosis is essential. Typical signs and symptoms are the thoracolumbar gibbus, shortened and plumped metacarpal bones, hip dysplasia, deformed ribs and ovoid vertebral bodies. Due to the typical deformation of the pelvis hip dislocation occurs often in childhood. Bilateral carpal tunnel syndrome is frequent. Bone marrow transplantation and enzyme replacement therapy are available. Orthopaedic interventions are based on individual therapeutic decisions and indications.
Collapse
Affiliation(s)
- B Link
- Villa metabolica, Klinikum der Johannes-Gutenberg-Universität, Langenbeckstrasse 2, 55131 Mainz, Deutschland.
| | | | | | | | | | | |
Collapse
|
35
|
Abstract
BACKGROUND Flicker light is an easy method to test sensory function after stress. The aim of this study was to determine the influence of flicker stress on temporal contrast sensitivity in healthy controls and patients with glaucomatous alteration of the optic disk. METHODS A commercially available full-field stimulator (Retiport, Roland Consult) equipped with white LEDs was modified to perform psychophysical tests. The patients underwent measurements of the recovery time interval from cessation of flicker stress until recognition of a pregiven flicker contrast after photo stress. In addition, we studied contrast sensitivity with a continuous flickering target and with a flicker burst protocol avoiding adaptation to prevailing flicker. All tests were performed at a constant retinal illumination and at a frequency of 37 Hz for provocation as well as for contrast sensitivity tests. SUBJECTS Normal healthy controls (40), "preperimetric" (62), and "perimetric" (52) open-angle glaucoma patients were studied. Exclusion criteria were age lower than 31 years, visual acuity under 0.6, and perimetric mean defect more than 9.5 dB. RESULTS Recovery time after flicker stress was significantly longer in patients than in normals and longer in perimetric than in preperimetric patients. Analysis in perimetric patients revealed a larger area under ROC for the provocation test (0.95) than in contrast sensitivity tests (continuous flicker method: 0.90, flicker burst mode: 0.84). CONCLUSION High-power LEDs which are installed in modern full-field devices can be used as a helpful tool to study psychophysical properties. In the present study it could be shown that threshold, adaptation, and recovery of temporal transfer characteristics are impaired in many patients with glaucoma.
Collapse
Affiliation(s)
- F K Horn
- Augenklinik mit Poliklinik, Friedrich-Alexander Universität Erlangen-Nürnberg, Schwabachanlage 6, 91054 Erlangen.
| | | | | | | | | |
Collapse
|
36
|
|
37
|
Friedberg JW, Huang J, Dillon H, Farber C, Feliciano S, Hainsworth J, Link B, Steis R, Vose J, Zelenetz A. Initial therapeutic strategy in follicular lymphoma (FL): An analysis from the National LymphoCare Study (NLCS). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7527] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7527 Background: Initial treatment strategies in FL include observation (obs), rituximab (R), chemotherapy ± R, and XRT. A recent study suggests initial therapy may impact FL survival (JCO 23:8447). NLCS is the first prospective observational study in the US designed to assess FL presentation, prognosis, treatment, and clinical outcomes. We describe initial therapeutic strategy in NLCS FL pts. Methods: FL pts diagnosed within 6 months with no prior lymphomas were recruited in this ongoing study. Data collected includes histology, stage, therapy, response, relapse and death. There is no specified treatment regimen. Results: From 3/04 to 11/05 1493 pts enrolled at 237 sites in the United States. Demographics have been initially reported at ASH 2005 (Blood 106:293a) and are comparable to SEER. Initial therapeutic strategy was: obs, 19%; R-monotherapy, 13%; chemo+R, 51%; XRT, 5%; chemo only, 4%. Chemo+R regimens were: R-CHOP, 59%; R-CVP, 19%; R-fludarabine based,11%; other, 11%. Choice to initiate therapy was associated with FLIPI, stage, and grade (p < 0.0001). Significant regional differences (p < 0.0001) were noted: obs was used in 13% of pts in Southeast and 31% in Northeast (NE); fludarabine-based R-chemo was used in 18% of pts in Southwest and only 3% in NE. Academic sites were more likely than community sites to treat pts on clinical trials (12% vs 4%). In pts treated with R or chemo+R, a higher FLIPI was not associated with decision to utilize chemotherapy. 26% of initially observed pts have switched to active therapy after a median of 2.8 months on obs since diagnosis; this was associated with baseline grade (III>II>I), but not stage or FLIPI. Conclusions: Diverse regimens are used for initial management of FL in the United States. Few pts are treated on clinical trials. Significant differences among regions and between center types suggest physician preference may drive initial therapy. Studies such as NLCS are needed to better understand the impact of initial therapy on short- and long-term outcomes. [Table: see text]
Collapse
Affiliation(s)
- J. W. Friedberg
- University of Rochester, Rochester, NY; Genentech, Inc., South San Francisco, CA; Leukemia Lymphoma Society, White Plains, NY; Simon Cancer Center, New York, NY; Oncology Consultants, Houston, TX; Sarah Cannon Research Institute, Nashville, TN; University of Iowa, Iowa City, IA; Atlanta Cancer Care, Atlanta, GA; University of Nebraska, Omaha, NE; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - J. Huang
- University of Rochester, Rochester, NY; Genentech, Inc., South San Francisco, CA; Leukemia Lymphoma Society, White Plains, NY; Simon Cancer Center, New York, NY; Oncology Consultants, Houston, TX; Sarah Cannon Research Institute, Nashville, TN; University of Iowa, Iowa City, IA; Atlanta Cancer Care, Atlanta, GA; University of Nebraska, Omaha, NE; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - H. Dillon
- University of Rochester, Rochester, NY; Genentech, Inc., South San Francisco, CA; Leukemia Lymphoma Society, White Plains, NY; Simon Cancer Center, New York, NY; Oncology Consultants, Houston, TX; Sarah Cannon Research Institute, Nashville, TN; University of Iowa, Iowa City, IA; Atlanta Cancer Care, Atlanta, GA; University of Nebraska, Omaha, NE; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - C. Farber
- University of Rochester, Rochester, NY; Genentech, Inc., South San Francisco, CA; Leukemia Lymphoma Society, White Plains, NY; Simon Cancer Center, New York, NY; Oncology Consultants, Houston, TX; Sarah Cannon Research Institute, Nashville, TN; University of Iowa, Iowa City, IA; Atlanta Cancer Care, Atlanta, GA; University of Nebraska, Omaha, NE; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S. Feliciano
- University of Rochester, Rochester, NY; Genentech, Inc., South San Francisco, CA; Leukemia Lymphoma Society, White Plains, NY; Simon Cancer Center, New York, NY; Oncology Consultants, Houston, TX; Sarah Cannon Research Institute, Nashville, TN; University of Iowa, Iowa City, IA; Atlanta Cancer Care, Atlanta, GA; University of Nebraska, Omaha, NE; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - J. Hainsworth
- University of Rochester, Rochester, NY; Genentech, Inc., South San Francisco, CA; Leukemia Lymphoma Society, White Plains, NY; Simon Cancer Center, New York, NY; Oncology Consultants, Houston, TX; Sarah Cannon Research Institute, Nashville, TN; University of Iowa, Iowa City, IA; Atlanta Cancer Care, Atlanta, GA; University of Nebraska, Omaha, NE; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - B. Link
- University of Rochester, Rochester, NY; Genentech, Inc., South San Francisco, CA; Leukemia Lymphoma Society, White Plains, NY; Simon Cancer Center, New York, NY; Oncology Consultants, Houston, TX; Sarah Cannon Research Institute, Nashville, TN; University of Iowa, Iowa City, IA; Atlanta Cancer Care, Atlanta, GA; University of Nebraska, Omaha, NE; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - R. Steis
- University of Rochester, Rochester, NY; Genentech, Inc., South San Francisco, CA; Leukemia Lymphoma Society, White Plains, NY; Simon Cancer Center, New York, NY; Oncology Consultants, Houston, TX; Sarah Cannon Research Institute, Nashville, TN; University of Iowa, Iowa City, IA; Atlanta Cancer Care, Atlanta, GA; University of Nebraska, Omaha, NE; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - J. Vose
- University of Rochester, Rochester, NY; Genentech, Inc., South San Francisco, CA; Leukemia Lymphoma Society, White Plains, NY; Simon Cancer Center, New York, NY; Oncology Consultants, Houston, TX; Sarah Cannon Research Institute, Nashville, TN; University of Iowa, Iowa City, IA; Atlanta Cancer Care, Atlanta, GA; University of Nebraska, Omaha, NE; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - A. Zelenetz
- University of Rochester, Rochester, NY; Genentech, Inc., South San Francisco, CA; Leukemia Lymphoma Society, White Plains, NY; Simon Cancer Center, New York, NY; Oncology Consultants, Houston, TX; Sarah Cannon Research Institute, Nashville, TN; University of Iowa, Iowa City, IA; Atlanta Cancer Care, Atlanta, GA; University of Nebraska, Omaha, NE; Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|
38
|
Zöllner IK, Weiland SK, Piechotowski I, Gabrio T, von Mutius E, Link B, Pfaff G, Kouros B, Wuthe J. No increase in the prevalence of asthma, allergies, and atopic sensitisation among children in Germany: 1992-2001. Thorax 2005; 60:545-8. [PMID: 15994260 PMCID: PMC1747445 DOI: 10.1136/thx.2004.029561] [Citation(s) in RCA: 127] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND From 1970 to 1990 increasing rates of asthma and allergic sensitisation were observed in several countries. The aim of this study was to investigate time trends in the prevalence of asthma and allergic sensitisation among school children in Germany between 1992 and 2001. METHODS Parental reports of asthma, hay fever, and wheezing and measurements of specific serum IgE antibodies were investigated in six serial cross sectional surveys of 9-11 year old school children in three study areas in south west Germany. RESULTS A total of 6762 school children of mean age 10 years (mean participation rate 77.9%) took part in the investigation in the three study areas. Over the 9 year study period no increase in the prevalence of current wheezing and asthma was observed. In addition, the prevalence of atopic sensitisation remained unchanged during the observation period. CONCLUSIONS These data, using parental reports and objective measures of allergy, suggest that there has been no further increase in the prevalence of asthma and atopy since 1992. The epidemic may thus have reached a plateau.
Collapse
Affiliation(s)
- I K Zöllner
- Department of Epidemiology and Health Reporting, Baden-Wuerttemberg State Health Office, Wiederholdstr 15, D-70174 Stuttgart, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Gabrio T, Broser S, Erdinger L, Felder-Kennel A, Fichtner G, Häberle E, Herrmann T, Kirsch H, Kouros B, Link B, Maisner V, Mann V, Päpke O, Piechotowski I, Rzonca E, Schick KH, Schrimpf M, Schröder S, Spöker-Maas K, Weidner U, Wuthe J, Zöllner I, Zöltzer D. Humanbiomonitoring-Untersuchungen von Organohalogenverbindungen - PCB, DDE; HCB, β- und γ-HCH, PCDD/PCDF, koplanaren PCB sowie polybromierten Biphenylethern. Gesundheitswesen 2005; 67:302-11. [PMID: 15856391 DOI: 10.1055/s-2005-858126] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Although PCB and PCB-containing materials are not processed for a long time, PCB is under discussion again and again caused by the pollution of indoor environments. To objectify the discussion, the dates of the PCB-biomonitoring, the organochlorine-compounds (DDE, HCB, beta-/gamma -HCH, PCDD/PCDF) and the polybrominated biphenyl ethers concerning the investigations within the project "Sentinel Health Departments" in Baden-Wurttemberg are represented. Additionally results from children from Kazakhstan (Aral-Sea area) and from teachers which are working in PCB polluted schools as well as from a long term investigated test person are reported. Blood concentrations of the following compounds decreased from 1996/97 to 2002/03: the sum of the concentration of PCB 138,153 and 180 decreased from 0.46 microg/L to 0.20 microg/L, DDE from 0.32 microg/L to 0.17 microg/, HCB from 0.20 microg/L to 0.08 microg/L, beta-HCH below the level of detection, I-TEQ NATO to 4.8 pg/g blood fat, TEQ WHO (without PCB) to 5.5 pg/g blood fat, PCB 126 to 18,8,pg/g blood fat and PCB 169 to 12.8 pg/g blood fat. The influence of breast feeding and the gender on the level of the pollution is conspicious. No local correlations were found in Baden-Wurttemberg, but they were found in comparison with the results of Kazakhstan (Aral-Sea area). The difficulty to produce time series while the analyzing pollutants are more and more decreasing, as well as the change of the calculation base of the summation of parameters like I-TEQ NATO to TEQ WHO are discussed.
Collapse
Affiliation(s)
- T Gabrio
- Landesgesundheitsamt Baden-Württemberg, Stuttgart.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Gabrio T, Broser S, Felder-Kennel A, Fichtner G, Kirsch H, Link B, Maisner V, Rzonca E, Schick KH, Schrimpf M, Schröder S, Spöker-Maas K, Weidner U, Wuthe J, Zöllner I. [Determination of mold concentrations in homes and schools in Baden-Württemberg]. Gesundheitswesen 2004; 66:528-35. [PMID: 15372355 DOI: 10.1055/s-2004-813453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
So far there have been rather few reliable and comparable data available on indoor pollution with mould. Following the publication of the Federal Environmental Agency and the Health Agency Baden-Württemberg which supports the assessment of mould pollution of indoor air, it seemed advisable to investigate as to how far these criteria can be used for the assessing the mould pollution in daily practice. The results of investigations of 130 homes and 117 classrooms in Baden-Württemberg. will be represented.
Collapse
Affiliation(s)
- T Gabrio
- Landesgesundheitsamt Baden-Württemberg, Stuttgart.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Link B, Kaminiski MS, Coleman M, Leonard JP. Phase II study of CVP followed by tositumomab and iodine I 131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin's lymphoma (NHL). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.6520] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- B. Link
- University of Iowa Hospitals and Clinics, Iowa City, IA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Weill Medical College of Cornell University, New York, NY
| | - M. S. Kaminiski
- University of Iowa Hospitals and Clinics, Iowa City, IA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Weill Medical College of Cornell University, New York, NY
| | - M. Coleman
- University of Iowa Hospitals and Clinics, Iowa City, IA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Weill Medical College of Cornell University, New York, NY
| | - J. P. Leonard
- University of Iowa Hospitals and Clinics, Iowa City, IA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Weill Medical College of Cornell University, New York, NY
| |
Collapse
|
42
|
Jovanovic S, Felder-Kennel A, Gabrio T, Kouros B, Link B, Maisner V, Piechotowski I, Schick KH, Schrimpf M, Schwenk M, Weidner U, Zöllner I. [Exposition and sensitisation to indoor allergens, house dust mite allergen and cat allergens]. Gesundheitswesen 2003; 65:457-63. [PMID: 12891478 DOI: 10.1055/s-2003-40803] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The study examined the exposure to biological indoor air agents and their possible role for allergies and respiratory tract illnesses of children. It was conducted as a case control study (atopic vs non-atopic children) at the four surveillance public health departments in Baden-Württemberg in the winter season 1999/2000 and included 379 children of the fourth class. The concentrations of the house dust mite antigens Der F1, Der p1, and Der Gr2 as well as cat allergen Fel d1 were determined in the children's bedrooms on the ground and in the mattress. Specific IgE-antibodies against allergens from house dust, mites and cat were determined in the serum of the children. For mite allergens the following medians ( micro g/g) were estimated in floor dust: Der p1 = 0.6, Der f1 = 2.3, Gr2 = 0.1; in mattresses: Der p1 = 1.2, Der f1 = 3.4, Gr2 = 0.3. The median of Fel d1 in floor dust was 0.2 microg/g, in mattresses 0.1 microg/g. Sensitisation to dust mite allergen was found to be more prevalent than sensitisation to cat. The distribution of sensitisation among the cases and controls is different. Among the cases, more subjects were sensitised to dust mites (32.9 %) and cat (13.1 %). Among the controls, 17.1 % were sensitised to dust mites and 4.1 % to cat. The results showed no direct association between the prevalence of allergies or respiratory tract illnesses and the indoor concentrations of the allergens. Possible reasons for these findings are discussed.
Collapse
Affiliation(s)
- S Jovanovic
- Landesgesundheitsamt Baden-Württemberg, Stuttgart.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Gabrio T, Benedikt G, Broser S, Felder-Kennel A, Fichtner G, Horras-Hun G, Jovanovic S, Kirsch H, Kouros B, Link B, Maisner V, Piechotowski I, Rzonca E, Schick KH, Schrimpf M, Schröder S, Schwenk M, Spöker-Maas K, Weidner U, Wuthe J, Zöllner I. [10 years of observation by public health offices in Baden-Württemberg--assessment of human biomonitoring for mercury due to dental amalgam fillings and other sources]. Gesundheitswesen 2003; 65:327-35. [PMID: 12772075 DOI: 10.1055/s-2003-39541] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Since 1992, in Baden-Württemberg, ten-year old children have been surveyed in the project "Sentinel Health Departments" to study their exposure to environmental pollutants and possible health effects. In the four study areas 1200 children have been investigated every year initially, since 1996 every second year. The data for mercury in body fluids are reported here. The decrease in the body burden of mercury as a result of the declining usage of dental amalgam fillings, was been verified. In 1992/93, of all the children who had been surveyed, the 95 percentile for the body burden of mercury was 3.1 microg/l and in 2000/01 1.35 microg/l. Also to be discussed is the reason why mercury-based cosmetic ointments seriously exceed the HBM-II-intervention-value. Because of using these ointments, concentrations of mercury in urine up to 1400 microg/l were found. A study within the project "Sentinel Health Departments" compared the concentrations of mercury in the urine of adults with those in blood and salvia. The results support the opinion that mercury in urine is appropriate for estimating the mercury uptake from dental amalgam fillings. It can be assumed that these results reflect the situation in the entire Federal Republic of Germany. The ten years' experience confirms that the concept of the "Sentinel Health Departments" is excellently suited to obtain data relevant for environmental health of children. Environmental health protection and the essential gathering of data for future health observation in Baden-Württemberg.
Collapse
Affiliation(s)
- T Gabrio
- Landesgesundheitsamt Baden-Württemberg, Stuttgart
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
|
45
|
Piechotowski I, Weidner U, Zöllner I, Gabrio T, Link B, Schwenk M. [Serum selenium levels in school children: results and health assessment]. Gesundheitswesen 2002; 64:602-7. [PMID: 12442220 DOI: 10.1055/s-2002-35540] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
BACKGROUND In Germany, where geogenic selenium concentrations are low, only few data on selenium status in children are available. Aim of the study was to investigate serum selenium concentrations of children in a population-based sample and to additionally investigate spatial and temporal differences. METHOD In three consecutive cross sectional studies the selenium concentration in serum was determined in 1,918 children (mean age 10.3 years) from four study areas. Potential factors of influence were assessed by questionnaires filled in by parents and physicians, respectively. Selenium determination was done by hydride atomic absorption spectrometry after microwave digestion. RESULTS Mean selenium concentrations for the subcollectives ranged from 54.5 +/- 10.5 micro g/l to 71.9 +/- 15.1 micro g/l. The minimum observed was 14 micro g/l, the maximum 216 micro g/l. Turkish children had lower selenium concentrations than German children and children of other nationality, respectively. Controlling for sex and year of investigation German children from Stuttgart had significantly lower selenium concentrations than children from Aulendorf/Bad Waldsee. In the same regression model for the period from 1995/96 to 1998/99 a decreasing trend was found to be significant. However, the regression model only explains a very small part of variance. CONCLUSIONS The selenium concentrations determined in this study are in the range also found in other studies in children from Germany. They are far below the toxicologically relevant range, which starts at about 600 micro g/l. The 5 th percentile in nearly all subcollectives was below the threshold limit of the lower tolerable selenium concentration of 45 micro g/l. For children from south Germany deficiency of selenium is therefore more to be suspected than a burden relevant to health. Selenium supplementation should however be considered thoroughly. Balanced nutrition is also a main factor for an optimum selenial supply.
Collapse
|
46
|
Gibson AD, Cheson BD, Link B, Oken MM. Updated Metaanalysis Finds That Interferon-α Improves Progression-Free and Overall Survival in Low-Grade Non-Hodgkin's Lymphoma When Administered with Chemotherapy That Contains Anthracyclines or Mitoxantrone. ACTA ACUST UNITED AC 2002. [DOI: 10.1016/s1526-9655(11)70253-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
47
|
Abstract
PURPOSE We evaluated the efficacy of topical brimonidine in visual field preservation and/or improvement in eyes undergoing controlled glaucoma. METHODS Seventy eyes of patients were trained with two different visual field test strategies: The Octopus Tendency Oriented Perimetry (TOP) G1 and the Frequency Doubling Technology (FDT) 30 degrees. Following 2-4 months of brimonidine treatment, there were significant improvements in visual field, as assessed using the TOP G1 strategy (p = 0.003). The FDT 30 degrees test revealed no statistically significant differences. CONCLUSIONS These data support the results of other studies, which indicate that brimonidine may increase mean sensitivity in visual field tests. Since it is known that the control of intraocular pressure does not fully protect glaucomatous eyes from visual field loss, it is possible that the neuroprotective qualities of brimonidine may contribute to visual field preservation in glaucomatous eyes.
Collapse
|
48
|
Stueve A, O'Donnell L, Link B. Gender differences in risk factors for violent behavior among economically disadvantaged African American and Hispanic young adolescents. Int J Law Psychiatry 2001; 24:539-557. [PMID: 11521425 DOI: 10.1016/s0160-2527(01)00083-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Affiliation(s)
- A Stueve
- Division of Epidemiology, Joseph L. Mailman School of Public Health, Columbia University, 600 West 168th Street, 7th Floor, PH-18 EPI/PET, New York, NY 10032, USA
| | | | | |
Collapse
|
49
|
Abstract
The rare case of a 3.5 month-old infant diagnosed with a endobronchial haemangioma is presented and discussed against a background of reference literary material. A main-bronchus sleeve resection with end-to-end anastomosis was performed without reduction of lung parenchyma. No complications were documented during the period of observation. The results of repeated bronchoscopy showed the post-operative period to be of a non-problematic nature.
Collapse
Affiliation(s)
- B Link
- Chirurgische Abteilung, Thoraxklinik Heidelberg gGmbH, Heidelberg
| | | | | | | |
Collapse
|
50
|
Treon SP, Agus DB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC. CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. J Immunother (1991) 2001; 24:272-279. [PMID: 11395644] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
SUMMARY: Waldenstrom's macroglobulinemia (WM, lymphoplasmacytic lymphoma) is a B-cell lymphoproliferative disorder in which CD20 is expressed on tumor cells from most patients. Several small studies have suggested a benefit from the anti-CD20 monoclonal antibody rituximab (Rituxan, MabThera) in patients with WM. In this retrospective study, we examined the outcome of 30 previously unreported patients with WM who received treatment with single-agent rituximab (median age 60; range 32-83 years old). The median number of prior treatments for these patients was 1 (range 0-6), and 14 patients (47%) received a nucleoside analogue before rituximab therapy. Patients received a median of 4.0 (1-11.3) infusions of rituximab (375 mg/m2). Three patients received steroids with their infusions for prophylaxis of rituximab-related infusion syndrome. Overall, treatment was well tolerated. Median immunoglobulin M (IgM) levels for all patients declined from 2,403 mg/dL (range 720-7639 mg/dL) to 1,525 mg/dL (range 177-5,063 mg/dL) after rituximab therapy (p = 0.001), with 8 of 30 (27%) and 18 of 30 (60%) patients demonstrating >50% and >25% decline in IgM, respectively. Median bone marrow lymphoplasmacytic (BM LPC) cell involvement declined from 60% (range 5-90%) to 15% (range 0-80%) for 17 patients for whom pre-and post-BM biopsies were performed (p < 0.001). Moreover, 19 of 30 (63%) and 15 of 30 (50%) patients had an increase in their hematocrit (HCT) and platelet (PLT) counts, respectively. Before rituximab therapy, 7 of 30 (23.3%) patients were either transfusion or erythropoietin dependent, whereas only 1/30 (3.3%) patients required transfusions (no erythropoietin) after rituximab. Overall responses after treatment with rituximab were as follows: 8 (27%) and 10 (33%) of the patients achieved a partial (PR) and a minor (MR) response, respectively, and an additional 9 (30%) of patients demonstrated stable disease (SD). No patients attained a complete response. The median time to treatment failure for responding (PR and MR) patients was 8.0 months (mean 8.4; range 3-20+ months), and 5.0 months (mean 6.1; range 3-12+ months) for patients with SD. These studies therefore demonstrate that rituximab is an active agent in WM. Marked increases in HCT and PLT counts were noted for most patients, including patients with WM who had MR or SD. A prospective clinical trial to more completely define the benefit of single-agent rituximab in patients with WM has been initiated by many of our centers.
Collapse
Affiliation(s)
- Steven P. Treon
- Dana Farber Cancer Institute, Boston, Massachusetts; Cedar Sinai Medical Center, Los Angeles, California; University of Iowa Hospitals and Clinics, Iowa City, Iowa; City of Hope National Medical Center, Duarte, California; Mayo Clinic, Rochester, Minnesota; UCLA Medical Center, Los Angeles, California; #Oncology/Hematology Care, University of Cincinnati, Cincinnati, Ohio; Kaiser Permanente, Vallejo, California; Walter Reed Army Medical Center, Washington, DC; New England Medical Center, Boston, Massachusetts, U.S.A.; and Huddinge University Hospital, Huddinge, Sweden
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|